Original Research
Accepted on 26 Nov 2024
Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma
in Gastrointestinal Cancers: Gastric and Esophageal Cancers